GlaxoSmithKline (GSK ... controller of Germany’s Stada and owner of UK consumer products maker Thornton & Ross. Stada already announced earlier this month it would buy a small portfolio of ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

GSK is on track to achieve its guidance for 2024 ... But more broadly speaking, the company has pointed out earlier, “the annualisation of product launches and stocking impacts" are seen ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK cuts 2024 vaccine sales forecast for second time this year Strong specialty medicines offset lower vaccine sales - CEO Q3 EPS beats market expectations Shares down 3.9% at 0958 GMT Oct 30 ...

MARIETTA, Pa. (WHTM) — A global biopharma company just announced that it will be investing up to $800 million to expand its long-time Lancaster County manufacturing facility. During a press ...

Phenylephrine:CVS pulls cold medicines with the ingredient Companies such as Procter & Gamble and GSK were among several accused ... or remove such drugs from the market. The Consumer Healthcare ...

GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...